FDA Clears Abbott Test for CLL Prognosis | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The US Food and Drug Administration has cleared for marketing Abbott's Vysis CLL FISH Probe Kit for determining the prognosis of patients with chronic lymphocytic leukemia.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.